Literature DB >> 6182344

Epidemiology of adverse reactions in anaesthesia in Germany and the Netherlands.

D Langrehr, D Newton, S Agoston.   

Abstract

We consider 292 anaphylactoid reactions from the own material (1964-1980) out of two different Departments of anesthesiology to attempt to review the continental epidemiology of this life-threatening adverse drug reaction. We conclude the following: The specialty of this type of adverse reaction is likely to prove a special separating name i.e. "anaphylactoid reaction". The overall frequency can be estimated for 1 : 400-600 in anesthesiology, a preponderance of females may be possible. There is no predictability of the reaction, not even by sophisticated history. But it is possible to avoid the development of severe shock by early diagnosis and immediate full causative therapy. With growing experience in diagnosis and therapy the mortality of anaphylactoid reaction should be irrelevant in the near future.

Mesh:

Substances:

Year:  1982        PMID: 6182344     DOI: 10.1007/bf01716964

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  Role of complement in induction of the allergic response.

Authors:  M B Pepys
Journal:  Nat New Biol       Date:  1972-05-31

Review 2.  Anaphylactoid reactions to i.v. substances.

Authors:  J Watkins
Journal:  Br J Anaesth       Date:  1979-01       Impact factor: 9.166

3.  [Adverse effects after dextran- and gelatin-preparations in infusion therapy. Clinical experiences in the anaphylactoid immediate reaction].

Authors:  D Langrehr; G Singbartl; R Neuhaus
Journal:  Klin Anasthesiol Intensivther       Date:  1975

4.  Predisposing factors in anaphylactoid reactions to anaesthetic drugs in an Australian population: the role of allergy, atopy and previous anaesthesia.

Authors:  M Laforest; D More; M Fisher
Journal:  Anaesth Intensive Care       Date:  1980-11       Impact factor: 1.669

5.  Adverse responses to i.v. anaesthetics.

Authors:  D Beamish; D T Brown
Journal:  Br J Anaesth       Date:  1981-01       Impact factor: 9.166

6.  [Randomised study on histaminelike side-effects of 5 common plasmasubstitutes in orthopedic surgery (author's transl)].

Authors:  B Schöning; H Koch
Journal:  Anaesthesist       Date:  1975-12       Impact factor: 1.041

7.  Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement.

Authors:  P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1969-01-01       Impact factor: 14.307

8.  Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release.

Authors:  M R Bristow; W S Sageman; R H Scott; M E Billingham; R E Bowden; R S Kernoff; G H Snidow; J R Daniels
Journal:  J Cardiovasc Pharmacol       Date:  1980 Sep-Oct       Impact factor: 3.105

9.  [Reducing of unwanted side effects of modified fluid gelatin by promethazine: controlled clinical trial with orthopaedic patints (author's transl)].

Authors:  B Schöning; H Koch
Journal:  Anaesthesist       Date:  1981-01       Impact factor: 1.041

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Allergy to muscle relaxants.

Authors:  J Birnbaum; D Vervloet
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 2.  Risk factors for allergic or pseudoallergic reactions in the perioperative period.

Authors:  D Charpin; M Pradal; D Vervloet
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 3.  Anaphylactic and anaphylactoid reactions. Clinical presentation.

Authors:  D A Moneret-Vautrin; M C Laxenaire
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

4.  Possible link between anaphylactoid reactions to anaesthetics and chemicals in cosmetics and biocides.

Authors:  A Weston; E S Assem
Journal:  Agents Actions       Date:  1994-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.